利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.022 秒)

    OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES
    1.
    发明申请
    OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES 审中-公开

    公开(公告)号：US20080112923A1

    公开(公告)日：2008-05-15

    申请号：US11949751

    申请日：2007-12-03

    申请人： Patrick HUGHES ,  James Burke ,  Joan-En Chang-Lin

    发明人： Patrick HUGHES ,  James Burke ,  Joan-En Chang-Lin

    IPC分类号： A61K31/765

    CPC分类号： A61K9/0051 ,  A61K9/0048 ,  A61K9/1647

    摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

    OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES
    2.
    发明申请
    OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES 审中-公开
    使用具有增强清除率的ALPHA-2 ADRENERGIC受体前体化合物进行的OCALAR治疗

    公开(公告)号：US20080112922A1

    公开(公告)日：2008-05-15

    申请号：US11949750

    申请日：2007-12-03

    申请人： Patrick HUGHES ,  James Burke ,  Joan-En Chang-Lin

    发明人： Patrick HUGHES ,  James Burke ,  Joan-En Chang-Lin

    IPC分类号： A61K31/765

    CPC分类号： A61K9/0051 ,  A61K9/0048 ,  A61K9/1647

    摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

    摘要翻译： 眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。 本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。 这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。 还描述了制备和使用本发明材料的方法。